Inulin,SCFA Production and Metabolic Response

Study Overview
=================
Brief Summary
-----------------
In this placebo controlled, double-blind, randomized crossover study the investigators will investigate in overweight/obese healthy male volunteers whether inulin administration will increase intestinal SCFA production, thereby investigating whether this will lead to acute metabolic effects.

Detailed Description
-----------------
Gut microbiota is being increasingly recognized as an important factor in fat distribution, insulin sensitivity and glucose and lipid metabolism. Accordingly, the intestinal microbiota could play an important role in the development of obesity and type 2 diabetes mellitus. The role of gut-derived short-chain fatty acids (SCFA), the formation of which is enhanced by microbial fermentation of fibre, is still controversial. At the present time, our understanding of the effects of SCFA on human metabolism (in gut or systemically) is still limited. The investigators hypothesize that the ingested prebiotic inulin is fermented into SCFA and these SCFA have metabolic effects.

Official Title
-----------------
SCFA Production and Their Metabolic Effects After Inulin Ingestion

Conditions
-----------------
Type 2 Diabetes Mellitus, Obesity

Intervention / Treatment
-----------------
* Dietary Supplement: 13C inulin
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Overweight, obese men Exclusion Criteria: athletes diabetes mellitus

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 13C inulin<br>13C inulin combined with an inulin load are administered orally | Dietary Supplement: 13C inulin<br>* Oral 13C inulin<br>|
| Placebo Comparator: Placebo<br>A placebo is administered orally | Other: Placebo<br>* Oral maltodextrin<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fat oxidation, energy expenditure | Fat oxidation and energy expenditure are measured after inulin ingestion | 1 study day for each administration | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hormones that influence substrate and energy metabolism | Insulin, GLP-1, PYY will be measured in plasma after inulin ingestion | 1 study day for each administration | 
| Circulating metabolites | Glucose, FFA, TG will be measured in plasma after inulin ingestion | 1 study day for each administration | 
| Appetite VAS scoring | Visual Analogue Scale for hunger and appetite are completed after inulin ingestion | 1 study day for each administration | 
| SCFAs | SCFA content (acetate, butyrate and propionate, unlabeled and 13C-labeled) are measured after inulin ingestion in plasma, faeces | 1 study day for each administration | 
| Breath sampling 13CO2 | In breath samples 13CO2 will be measured after inulin ingestion | 1 study day for each administration |